Biopharmaceutical companies have announced an abundance of investment in their companies from US government sources recently, which adds to the flurry of new investment funds backing drug developers, including the new €360m ($415.9m) venture capital fund revealed by Forbion on Oct. 1.
Forbion joins Hillhouse Capital, which closed a $10.6bn private equity fund in September to invest across several industries, including health care, as an investor with a renewed commitment to life science opportunities. (Also see "Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B" - Scrip, 26 September, 2018.) Similarly, Vivo Capital closed a $635m fund last month to back small and mid-cap public life science companies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?